CLDN3 and prostate cancer: In prostate cancer specifically, claudin-3 has been shown to correlate with advanced tumor stage and recurrence, although the immunohistochemical expression profiles varied in an examination of 141 cases of prostate cancer, where matched adjacent normal epithelium was compared to prostatic adenocarcinoma (PCa).